These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17239587)

  • 41. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
    Yang Y; Shi L; Zhou Y; Li HQ; Zhu ZW; Zhu HL
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6653-6. PubMed ID: 20943391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis of 5-substituted-1H-indol-2-yl-1H-quinolin-2-ones: a novel class of KDR kinase inhibitors.
    Kuethe JT; Wong A; Qu C; Smitrovich J; Davies IW; Hughes DL
    J Org Chem; 2005 Apr; 70(7):2555-67. PubMed ID: 15787543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
    Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, Synthesis, and Structure-Activity Relationship Study of Pyrazolones as Potent Inhibitors of Pancreatic Lipase.
    Zhang J; Yang Y; Qian XK; Song PF; Zhao YS; Guan XQ; Zou LW; Bao X; Wang H
    ChemMedChem; 2021 May; 16(10):1600-1604. PubMed ID: 33527731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 4-aminopyrimidine-5-carbaldehyde oximes as potent VEGFR-2 inhibitors. Part II.
    Huang S; Li R; LaMontagne KR; Greenberger LM; Connolly PJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1815-8. PubMed ID: 21316232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Property-based design of KDR kinase inhibitors.
    Fraley ME; Hoffman WF; Arrington KL; Hungate RW; Hartman GD; McFall RC; Coll KE; Rickert K; Thomas KA; McGaughey GB
    Curr Med Chem; 2004 Mar; 11(6):709-19. PubMed ID: 15032725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.
    McElroy WT; Tan Z; Basu K; Yang SW; Smotryski J; Ho GD; Tulshian D; Greenlee WJ; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1335-9. PubMed ID: 22227212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides.
    Tester R; Tan X; Luedtke GR; Nashashibi I; Schinzel K; Liang W; Jung J; Dugar S; Liclican A; Tabora J; Levy DE; Do S
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2560-3. PubMed ID: 20346659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis of novel KDR kinase inhibitors through catalytic reductive cyclization of o-nitrobenzylcarbonyl compounds.
    Wong A; Kuethe JT; Davies IW; Hughes DL
    J Org Chem; 2004 Oct; 69(22):7761-4. PubMed ID: 15498012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.
    Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
    Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP
    ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.
    Wickens P; Kluender H; Dixon J; Brennan C; Achebe F; Bacchiocchi A; Bankston D; Bierer D; Brands M; Braun D; Brown MS; Chuang CY; Dumas J; Enyedy I; Hofilena G; Hong Z; Housley T; Jones B; Khire U; Kreiman C; Kumarasinghe E; Lowinger T; Ott-Morgan R; Perkins L; Phillips B; Schoenleber R; Scott WJ; Sheeler R; Redman A; Sun X; Taylor I; Wang L; Wilhelm S; Zhang X; Zhang M; Sullivan E; Carter C; Miglarese M; Levy J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4378-81. PubMed ID: 17574417
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
    Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.
    Underiner TL; Ruggeri B; Aimone L; Albom M; Angeles T; Chang H; Hudkins RL; Hunter K; Josef K; Robinson C; Weinberg L; Yang S; Zulli A
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2368-72. PubMed ID: 18343109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2.
    Stieber F; Mazitschek R; Soric N; Giannis A; Waldmann H
    Angew Chem Int Ed Engl; 2002 Dec; 41(24):4757-61. PubMed ID: 12481350
    [No Abstract]   [Full Text] [Related]  

  • 57. Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Gillespie P; Pietranico-Cole S; Myers M; Bilotta JA; Conde-Knape K; Fotouhi N; Goodnow RA; Guertin KR; Hamilton MM; Haynes NE; Liu B; Qi L; Ren Y; Scott NR; So SS; Spence C; Taub R; Thakkar K; Tilley JW; Zwingelstein C
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2707-11. PubMed ID: 24815509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
    Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
    Ho GD; Yang SW; Smotryski J; Bercovici A; Nechuta T; Smith EM; McElroy W; Tan Z; Tulshian D; McKittrick B; Greenlee WJ; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1019-22. PubMed ID: 22222034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.